Navigation Links
Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects
Date:9/24/2009

ody in development for the potential treatment of advanced ovarian cancer. In vitro, farletuzumab appears to have antiproliferative and cytotoxic activities in tumor cells that over express FRA.

A randomized global Phase III study to test farletuzumab in combination with platinum and taxane (P/T) in platinum-sensitive ovarian cancer subjects is currently underway. For more information about the Phase III trial, please visit www.far-trials.com or www.clinicaltrials.gov.

About Morphotek

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, is a biopharmaceutical company specializing in the development of protein and antibody products through the use of a proprietary gene evolution technology. The technology has been successfully applied to a broad variety of cell lines and organisms to yield genetically diverse offspring that are suitable for product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease. For more information, please visit www.morphotek.com.

Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies
'/>"/>

SOURCE Morphotek(R), Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
2. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
3. ClariVein(TM) Catheter for Varicose Veins: Further Clinical Trial Results to Be Presented
4. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
5. New Micro-Bland Embolization Technique with Embozene(TM) Microspheres to Be Presented at the International Medical Conference in Lisbon, Portugal
6. QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting
7. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2009
8. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
9. Late Breaking Clinical Trials Presented at HFSA 13th Annual Scientific Meeting
10. Study on PLC Systems TMR Therapy With Stem Cells Presented at ESC 2009
11. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
(Date:7/30/2015)... 2015  NanoSmart Pharmaceuticals, Inc., a private pharmaceutical ... Orphan Drug Designation from the Food and Drug ... uses NanoSmart,s proprietary drug delivery platform. The drug ... treatment of Ewing,s sarcoma, a rare type of ... Drug Designation on the basis of a plausible ...
(Date:7/30/2015)... 2015 Flexpoint Ford, a private equity firm ... announced that it has entered into a partnership with ... to form Kastle Therapeutics, LLC (Kastle).  The new company, ... on acquiring, developing and commercializing pharmaceuticals targeted toward diseases ... select therapies already approved for marketing, as well as ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 3
... 22, 2011 United Seating & Mobility (USM) ... transaction with Central Kentucky Mobility (CKM) to acquire and merge ... for Lexington, Louisville, as well as central, eastern and southern ... team strengthens our position within a core market for us ...
... WOONSOCKET, R.I., July 22, 2011 CVS Caremark Corporation ... conference call on Thursday, August 4, 2011, at 8:30 ... second quarter 2011 financial results. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) ... will be broadcast simultaneously through the Investor Relations portion ...
Cached Medicine Technology:CVS Caremark Corporation to Hold Second Quarter 2011 Conference Call 2
(Date:7/30/2015)... ... July 30, 2015 , ... ... Biz Report, which takes a look at small, medium, and large businesses making ... business expert, conducted the business review and shared with viewers how DevExpress has ...
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care At Home, a high-quality ... Bernardino, recently announced that the Centers for Medicare and Medicaid (CMS) have awarded its ... care providers. 24/7 Care At Home’s agency is one of three top Orange County ...
(Date:7/30/2015)... ... , ... The need for accessibility is never greater than when we find ... well as visiting friends and family during these critical moments, hospitals around the Pennsylvania ... powered by ChargeItSpot , a Philadelphia-based startup that recently secured a $4M Series ...
(Date:7/30/2015)... ... 2015 , ... OncLive®’s extensive roster of Strategic ... Cancer Center (JCCC) mutually agreed to collaborate on projects that promote groundbreaking ... groups will help spread the news about the center’s leading-edge cancer research, robust ...
(Date:7/30/2015)... ... 2015 , ... Zejax is a New Way of Training ... , World renown body weight trainer, Paul Ziachik, announces today that he ... a person’s training capability. , The American College of Sports Medicine states that ...
Breaking Medicine News(10 mins):Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2
... , TUESDAY, March 1 (HealthDay News) -- For ... to relieve symptoms and result in major improvements in ... Up to 20 percent of women in their childbearing ... Not all fibroids cause symptoms, but some patients experience ...
... is a common problem in patients with chronic rhinosinusitis ... function, and quality of life (QOL), according to new ... Otolaryngology Head and Neck Surgery . ... and may have the following symptoms for 12 weeks ...
... 1, 2011) Endoscopic removal of pre-cancerous cells ... recommended rather than surveillance, according to a new ... Esophagus," published by the American Gastroenterological Association (AGA) ... Gastroenterology , the official journal of the ...
... Lymph node dissection, the current standard surgical treatment for ... screen-detected early stage cases , according to a study published ... Oncology (JTO), the official journal of the International Association ... nodal involvement is very low in early-stage cancers with a ...
... and Opportunistic Infections is taking place at the Hynes ... 2. Day two of this major HIV/AIDS research conference ... the National Institute of Allergy and Infectious Diseases (NIAID), ... HIV/TB Co-Infection , Diane Havlir, M.D., of the ...
... hundred years ago are being used in the development of ... time old bones have been used in this way. ... latest computer modelling techniques developed at the University of Leeds, ... With Engineering and Physical Sciences Research Council (EPSRC) funding, ...
Cached Medicine News:Health News:Uterine Fibroid Treatments Seem to Boost Quality of Life 2Health News:Effects of depression on quality of life improvement after endoscopic sinus surgery 2Health News:Watchful waiting no longer recommended for some high-risk Barrett's esophagus patients 2Health News:Watchful waiting no longer recommended for some high-risk Barrett's esophagus patients 3Health News:Lymph node dissection is not essential in small screen-detected lung cancers, new research shows 2Health News:CROI -- Day 2: Selected highlights of NIH-supported research 2Health News:CROI -- Day 2: Selected highlights of NIH-supported research 3Health News:CROI -- Day 2: Selected highlights of NIH-supported research 4Health News:Learning from old bones to treat modern back pain 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: